Inflammatory cells remain in blood after treatment of severe asthma, suggests research Dr. Kamal Kant Kohli11 July 2025 8:15 AM ISTBiological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet in Sweden shows that some...
Medical Bulletin 01/Jul/2025 Dr. Bhumika Maikhuri1 July 2025 3:00 PM ISTHere are the top medical news for the day:Why Asthma Often Comes Back After Stopping Biologic Drugs?While biological drugs have significantly improved...
Why Asthma Often Comes Back After Stopping Biologic Drugs? Study Sheds Light Dr. Bhumika Maikhuri1 July 2025 8:00 AM ISTWhile biological drugs have significantly improved the quality of life for individuals with severe asthma, a new study from the Karolinska Institutet...
Dupilumab used for atopic dermatitis Linked to Increased Risk of Psoriasis: JAMA Jacinthlyn Sylvia23 Jun 2025 8:30 PM ISTA new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating atopic dermatitis, is...
FDA Approves Dupilumab as First Targeted Treatment for Bullous Pemphigoid Dr. Kamal Kant Kohli22 Jun 2025 8:45 PM ISTThe US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous pemphigoid, a rare blistering...
Sanofi Dupixent gets USFDA nod for bullous pemphigoid treatment in adults Ruchika Sharma20 Jun 2025 12:15 PM ISTParis: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment of adult patients...
Dupilumab Shows Promise as Novel Treatment for Necrobiosis Lipoidica: Case Report Medha Baranwal15 Jun 2025 8:15 PM ISTUSA: A recent case report published in The Open Dermatology Journal has brought attention to the successful use of dupilumab-a biologic commonly...
Sanofi-Regeneron Dupixent data reinforce use in atopic dermatitis patients with skin of color Ruchika Sharma9 Jun 2025 1:12 PM ISTParis: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent (dupilumab) in adults and...
Study observes favourable safety profile of dupilumab in pregnancy Jacinthlyn Sylvia15 May 2025 9:00 PM ISTA new study published in the Journal of the European Academy of Dermatology and Venerology found dupilumab to have a favorable safety profile during...
Dupilumab Reduces COPD Exacerbations, Shows Promise for Personalized Treatment: Study Finds Medha Baranwal29 April 2025 8:00 PM ISTUSA: A pooled analysis of two phase 3, randomized, double-blind, placebo-controlled trials has demonstrated the effectiveness of dupilumab as an...
FDA Approves Dupilumab as First New Targeted Therapy for Chronic Spontaneous Urticaria in Over a Decade Dr. Kamal Kant Kohli21 April 2025 9:15 PM ISTThe US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of chronic spontaneous urticaria (CSU) in patients aged...
